Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised,
multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation
using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism,
or cardiovascular death in patients with AHRE and at least two stroke risk factors but
without AF. The trial will be conducted in several European countries.
Phase:
Phase 3
Details
Lead Sponsor:
Atrial Fibrillation Network German Atrial Fibrillation Network
Collaborators:
Daiichi Sankyo Europe, GmbH Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)